MannKind Corporation (NasdaqGM: MNKD)
Health Care · Biotechnology · US
$3.29
-13.42% today · -32.6% 1Y
MannKind Corporation (NasdaqGM: MNKD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.06B and employs 592 people.
Over the last twelve months the share price has lost 32.6%, trading between 2.23 and 6.51.
Tweenvest scores MannKind Corporation across four factors: quality 46/100, value 58/100, growth 100/100. Its strongest factor is growth.
MNKD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.06B
- Revenue (TTM)
- $393.63M
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 1.08
- 52-week high
- $6.51
- 52-week low
- $2.23
- Avg volume (3M)
- —
- Shares outstanding
- 321.54M
- Employees
- 592
- Next earnings
- —
About MannKind Corporation
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
- ISIN
- US56400P7069
- Founded
- 1991
- Listed since
- Jul 28, 2004
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Changchun BCHT Biotechnology Co.SHSE: 688276 | $1.10B | CN¥17.79 | -0.89% |
| GC Biopharma Corp.KOSE: A006280 | $1.10B | ₩129,400.00 | +2.86% |
| Chengdu Kanghua Biological Products Co., Ltd.SZSE: 300841 | $1.07B | CN¥55.26 | -1.95% |
| Beijing Strong Biotechnologies,Inc.SZSE: 300406 | $1.06B | CN¥12.14 | +1.68% |
| CStone PharmaceuticalsSEHK: 2616 | $1.03B | HK$5.09 | -9.99% |
| MeiraGTx Holdings plcNasdaqGS: MGTX | $1.03B | $10.69 | -0.93% |
| Immatics N.V.NasdaqCM: IMTX | $1.02B | $7.43 | -2.11% |
| Kolon TissueGene, Inc.KOSDAQ: A950160 | $1.01B | ₩16,030.00 | -0.62% |
Figures last refreshed Oct 11, 2026.